Climate Change Data

Senhwa Biosciences, Inc.

Climate Impact & Sustainability Data (2018, 2019, 2020, 2022, 2023)

Reporting Period: 2018

Environmental Metrics

ESG Focus Areas

  • Governance
  • Research and Development

Social Achievements

  • Established employee welfare measures including labor and national health insurance, group insurance, holiday bonuses/subsidies/leisure, and employee stock options.

Governance Achievements

  • Established a Remuneration Committee.
  • Formulated Corporate Governance Best Practice Principles.
  • Implemented an internal control system.
  • Established Ethical Corporate Management Best Practice Principles.

Climate Goals & Targets

Long-term Goals:
  • Maintain at least two clinical trial development projects.
  • Aim for the global market and actively seek broader alliances.
Short-term Goals:
  • Complete Phase I/Expansion cohorts for CX-5461 and CX-4945.
  • Complete plans for clinical trials for new indications of CX-5461.
  • Apply for IND trials for new indications of CX-5461.
  • Launch and execute trials for new indications of CX-5461.
  • Complete phase I/II international multicenter clinical trials for CX-4945.
  • Complete data analysis and report of international multi-center clinical trials for CX-4945.
  • Execute phase I/Expansion cohorts for CX-4945 for basal cell carcinoma.
  • Assist PBTC in performing phase I/II clinical trials for CX-4945 for medulloblastoma.

Environmental Challenges

  • Sustained cumulative losses.
  • High R&D investment and long development timelines for new drugs.
  • Lack of professional talent.
Mitigation Strategies
  • Focus on midstream development of new drugs to reduce risk and increase efficiency.
  • Employ high-level biotechnology talents and professional medical consultants.
  • Seek cooperation with renowned international institutions for funding of clinical trials.
  • Portfolio management strategy to reduce development risks.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: International Financial Reporting Standards

Third-party Assurance: PricewaterhouseCoopers, Taiwan

Awards & Recognition

  • 14th National Innovation Award

Reporting Period: 2019

Environmental Metrics

Social Achievements

  • Established a welfare system that provides stability for employees' lives and a sound education and training system, which builds good relations with employees based on mutual trust and reliance.

Governance Achievements

  • Established a Remuneration Committee to improve and strengthen the management functions of the Board of Directors.
  • Amended the "Regulations Governing Evaluation of Board Performance" in March 2019, and a performance self-evaluation survey will be distributed to all Directors before the end of the first quarter in the following year.

Climate Goals & Targets

Short-term Goals:
  • Continue to advance development projects of the new drug candidate Pidnarulex (CX-5461), and to plan and prepare for Phase II clinical trials.
  • Continue to advance development projects for the new drug candidate Silmitasertib (CX-4945), including: (1) continue Phase II cholangiocarcinoma clinical trials; (2) continue Phase II basal cell carcinoma clinical trials; (3) assist the Stanford University medical research team to initiate the children's brain tumor-medulloblastoma human clinical trials.

Environmental Challenges

  • The development of a new drug requires substantial investments and a long period of time.
  • Lack of professional talent.
Mitigation Strategies
  • Senhwa's operating model focuses mainly on the development of new drugs for clinical trials that verify the effectiveness of drugs in humans and involves less in early drug discovery or laboratory cell research work.
  • The Company employs high-level biotechnology talents and professional medical consultants in various fields, thus ensuring that the original transferred technology can be successfully undertaken in a short period of time. We also plan and advance various projects and work with suppliers and international contract research organizations (CROs) to maintain stable and interacting partnerships.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Period: 2020

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Established Remuneration Committee and Audit Committee

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Advance development of Pidnarulex (CX-5461) and Silmitasertib (CX-4945) in clinical trials.
  • Secure regional licensing or collaborations.

Environmental Challenges

  • COVID-19 pandemic impacted R&D expenditure and patient enrollment in clinical trials.
  • Accumulated losses
Mitigation Strategies
  • Capital increase of NT$180 million to enrich working capital.
  • Adjusted R&D budget and timelines.
  • Actively sought strategic alliances and licensing partners.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: PricewaterhouseCoopers, Taiwan

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Pidnarulex (CX-5461) and Silmitasertib (CX-4945)

Awards & Recognition

  • Not disclosed

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Not disclosed
Mitigation Strategies
  • Not disclosed

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Established a welfare system and a sound educational training system that provides stability for employees’ lives to build healthy relationships with employees based on mutual trust and reliance.
  • No occupational accidents or fire incidents as of the end of 2023.

Governance Achievements

  • Established an Audit Committee and a Remuneration Committee.
  • Amended the "Regulations Governing Evaluation of Board Performance", "Regulations Governing the Prevention of Insider Trading", "Corporate Governance Best Practice Principles", and "Sustainable Development Best Practice Principles".

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Continue to advance the development projects of the drug candidate Pidnarulex (CX5461) used in the solid tumor clinical trials in Canada and the U.S and the NExT Program.
  • Continue to advance development projects for the drug candidate Silmitasertib (CX-4945), including: (1) close clinical trial of BCC; (2) assist medical research team of Stanford University to advance clinical trial of pediatric brain tumor-medulloblastoma; and (3) anti-inflammatory clinical trials for Community-Acquired Pneumonia.

Environmental Challenges

  • The Company had important progress on results of all novel drug R&D projects in 2023, but the revenue has not generated yet.
  • The major expenditure item for the Company's consolidated income and expenditure for 2023 was the expenditure for the development of novel drugs.
  • Drug discoveries require substantial investments in time and capital.
  • Lack of professional talent.
Mitigation Strategies
  • The Company adopts professional project management methods to integrate domestic and foreign R&D resources.
  • The Company will continue to adhere to the model of “Development in parallel with Research” for the drug development in 2024.
  • The Company employs senior biotech talents and professional medical consultants in different fields.
  • The Company organizes and promotes various projects and work with suppliers and international Contract Research Organizations (CROs) to establish stable partnerships with continual interactions.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed